Potential association of and variant alleles with increased risk for palbociclib toxicity.

This study evaluated associations between and variants in other pharmacogenes (, , , , ) and the risk for palbociclib-associated toxicities. Two hundred cancer patients who received standard-of-care palbociclib were genotyped and associations with toxicity were evaluated retrospectively. No significant associations were found for , , _rs1045642, _rs2231142, _rs3212986 and _rs11615.

Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.

The pharmacokinetics and pharmacodynamics of vemurafenib are characterized by a wide interpatient variability. Since multiple polymorphic enzymes and drug transporters are involved in vemurafenib pharmacokinetics, we studied associations of polymorphisms on vemurafenib-associated toxicities. Prospectively collected samples of 97 melanoma patients treated with vemurafenib alone (n = 62) or in combination with cobimetinib (n = 35) were genotyped for (3435C>T), (421C>A, 34G>A) and (, 15389C>T) polymorphisms.

Pharmacogenomics and histone deacetylase inhibitors.

The histone deacetylase inhibitor valproic acid (VPA) has been used for many decades in neurology and psychiatry. The more recent introduction of the histone deacetylase inhibitors (HDIs) belinostat, romidepsin and vorinostat for treatment of hematological malignancies indicates the increasing popularity of these agents. Belinostat, romidepsin and vorinostat are metabolized or transported by polymorphic enzymes or drug transporters.